<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582880</url>
  </required_header>
  <id_info>
    <org_study_id>10-03-020</org_study_id>
    <nct_id>NCT01582880</nct_id>
  </id_info>
  <brief_title>Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis</brief_title>
  <official_title>The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph B. Ciolino, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the pilot study is to test the efficacy and safety of riboflavin/Ultraviolet A
      (UVA) cross-linked human donor corneas as carriers for the Boston Keratoprosthesis (Boston
      KPro) in patients with higher risk for corneal melting (keratolysis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The corneal cross-linking technique has been shown to strengthen the cornea and resist
      degradation by the body's own enzymes. The use of highly-resistant donor corneas is meant to
      eliminate the serious post-operative complication of corneal melting (keratolysis) that
      repeatedly occurs in Boston KPro patients with severe ocular burns, autoimmune and
      cicatrizing diseases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Corneal Thickness at 1 Millimeter</measure>
    <time_frame>measured at week 4, 6, 26, 32, 52</time_frame>
    <description>The average carrier graft thickness over the first year of postoperative follow-up. The corneal thickness was measured at each visit using AS-OCT imaging 1 mm away from the KPro stem at 3, 6, 9, and 12 o'clock. The individual corneal thickness measurements (3, 6, 9, and 12 o'clock) where then averaged. The average corneal thickness measurements for week 4, 6, 26, 32 and 52 are reported below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Corneal Thickness at 2 Millimeter</measure>
    <time_frame>measured at week 4, 6, 26, 32, 52</time_frame>
    <description>The average carrier graft thickness over the first year of postoperative follow-up. The corneal thickness was measured at each visit using AS-OCT imaging 2 mm away from the KPro stem at 3, 6, 9, and 12 o'clock. The individual corneal thickness measurements (3, 6, 9, and 12 o'clock) where then averaged. The average corneal thickness measurements for week 4, 6, 26, 32 and 52 are reported below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Occurrences of Vitritis (Sterile or Infectious) Ulcers</measure>
    <time_frame>post op week 52</time_frame>
    <description>Number of occurrence of vitritis (sterile or infectious) ulcers. Incidences of ulcers were collected by way of slit lamp photography from time of surgery to final visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Safety</measure>
    <time_frame>measured at day 1, and week 1, 4, 8, 12, 16, 24, 36, 52</time_frame>
    <description>Incidence and severity of ocular adverse events during the study (ophthalmic examination, adverse events spontaneously reported)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Safety</measure>
    <time_frame>measured at day 1, and week 1, 4, 8, 12, 16, 24, 36, 52</time_frame>
    <description>Incidence and severity of systemic adverse events during the study (clinical laboratory, adverse events spontaneously reported).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Chemical Injuries</condition>
  <condition>Unspecified Complication of Corneal Transplant</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Ocular Cicatricial Pemphigoid</condition>
  <condition>Stevens Johnson Syndrome</condition>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Other Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Riboflavin Cross-linked donor cornea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Used to treat donor cornea before implantation</description>
    <arm_group_label>Riboflavin Cross-linked donor cornea</arm_group_label>
    <other_name>Riboflavin (vitamin B2) 0.1% solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          2. Age &gt; 18 years.

          3. A negative urine pregnancy test.

          4. Candidate for a Boston Keratoprosthesis/Corneal transplant.

          5. Generally good stable overall health.

          6. Patients with an eye at risk for a cornea sterile ulcer which includes:

               -  Chemical injuries.

               -  Autoimmune diseases (ocular cicatricial pemphigoid, Stevens Johnson Syndrome,
                  systemic lupus erythematosus, rheumatoid arthritis, or other autoimmune
                  diseases).

               -  History of previous sterile corneal ulceration requiring a cornea transplant.

        Exclusion Criteria:

          1. Age &lt; 18 years.

          2. Inability to provide written informed consent and comply with study assessments for
             the full duration of the study.

          3. Pregnant or lactating women.

          4. No or minimal tear production.

          5. Ocular or periocular malignancy.

          6. Inability to wear a contact lens due to lid abnormalities or shortened fornix.

          7. Signs of current infection, including fever and current treatment with antibiotics.

          8. Participation in another simultaneous medical investigation or trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Ciolino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2012</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>June 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2017</results_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts Eye and Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Joseph B. Ciolino, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Keratoprosthesis</keyword>
  <keyword>sterile cornea ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Pemphigoid, Bullous</mesh_term>
    <mesh_term>Stevens-Johnson Syndrome</mesh_term>
    <mesh_term>Pemphigoid, Benign Mucous Membrane</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Riboflavin Cross-linked Donor Cornea</title>
          <description>the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
Riboflavin: Used to treat donor cornea before implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Riboflavin Cross-linked Donor Cornea</title>
          <description>the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
Riboflavin: Used to treat donor cornea before implantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52">Standard Deviation is not applicable for a single participant</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>corneal thickness measured at 1mm one day post op</title>
          <description>&quot;corneal thickness measured at 1mm one day post op&quot; is the baseline measurement for this study. This study evaluated cross-linked cornea tissue versus standard of care cornea tissue after transplant procedure. Therefore the measurement at one day post op is the baseline measurement.</description>
          <units>µm</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>corneal thickness measured at 2mm one day post op</title>
          <description>&quot;corneal thickness measured at 2mm one day post op&quot; is the baseline measurement for this study. This study evaluated cross-linked cornea tissue versus standard of care cornea tissue after transplant procedure. Therefore the measurement at one day post op is the baseline measurement.</description>
          <units>µm</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Corneal Thickness at 1 Millimeter</title>
        <description>The average carrier graft thickness over the first year of postoperative follow-up. The corneal thickness was measured at each visit using AS-OCT imaging 1 mm away from the KPro stem at 3, 6, 9, and 12 o'clock. The individual corneal thickness measurements (3, 6, 9, and 12 o'clock) where then averaged. The average corneal thickness measurements for week 4, 6, 26, 32 and 52 are reported below.</description>
        <time_frame>measured at week 4, 6, 26, 32, 52</time_frame>
        <population>52 year old white male patient</population>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin Cross-linked Donor Cornea</title>
            <description>The donor cornea used as a carrier for the Boston Keratoprosthesis underwent crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
Riboflavin: Used to treat donor cornea before implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Corneal Thickness at 1 Millimeter</title>
          <description>The average carrier graft thickness over the first year of postoperative follow-up. The corneal thickness was measured at each visit using AS-OCT imaging 1 mm away from the KPro stem at 3, 6, 9, and 12 o'clock. The individual corneal thickness measurements (3, 6, 9, and 12 o'clock) where then averaged. The average corneal thickness measurements for week 4, 6, 26, 32 and 52 are reported below.</description>
          <population>52 year old white male patient</population>
          <units>micrometer</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 26 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 32 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 52 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Corneal Thickness at 2 Millimeter</title>
        <description>The average carrier graft thickness over the first year of postoperative follow-up. The corneal thickness was measured at each visit using AS-OCT imaging 2 mm away from the KPro stem at 3, 6, 9, and 12 o'clock. The individual corneal thickness measurements (3, 6, 9, and 12 o'clock) where then averaged. The average corneal thickness measurements for week 4, 6, 26, 32 and 52 are reported below.</description>
        <time_frame>measured at week 4, 6, 26, 32, 52</time_frame>
        <population>52 year old white male patient</population>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin Cross-linked Donor Cornea</title>
            <description>The donor cornea used as a carrier for the Boston Keratoprosthesis underwent crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
Riboflavin: Used to treat donor cornea before implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Corneal Thickness at 2 Millimeter</title>
          <description>The average carrier graft thickness over the first year of postoperative follow-up. The corneal thickness was measured at each visit using AS-OCT imaging 2 mm away from the KPro stem at 3, 6, 9, and 12 o'clock. The individual corneal thickness measurements (3, 6, 9, and 12 o'clock) where then averaged. The average corneal thickness measurements for week 4, 6, 26, 32 and 52 are reported below.</description>
          <population>52 year old white male patient</population>
          <units>micrometer</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 26 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 32 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 52 corneal thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Occurrences of Vitritis (Sterile or Infectious) Ulcers</title>
        <description>Number of occurrence of vitritis (sterile or infectious) ulcers. Incidences of ulcers were collected by way of slit lamp photography from time of surgery to final visit.</description>
        <time_frame>post op week 52</time_frame>
        <population>52 year old white male</population>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin Cross-linked Donor Cornea</title>
            <description>The donor cornea used as a carrier for the Boston Keratoprosthesis underwent crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
Riboflavin: Used to treat donor cornea before implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Occurrences of Vitritis (Sterile or Infectious) Ulcers</title>
          <description>Number of occurrence of vitritis (sterile or infectious) ulcers. Incidences of ulcers were collected by way of slit lamp photography from time of surgery to final visit.</description>
          <population>52 year old white male</population>
          <units>occurrences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Safety</title>
        <description>Incidence and severity of ocular adverse events during the study (ophthalmic examination, adverse events spontaneously reported)</description>
        <time_frame>measured at day 1, and week 1, 4, 8, 12, 16, 24, 36, 52</time_frame>
        <population>52 year old white male</population>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin Cross-linked Donor Cornea</title>
            <description>The donor cornea used as a carrier for the Boston Keratoprosthesis underwent crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
Riboflavin: Used to treat donor cornea before implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Safety</title>
          <description>Incidence and severity of ocular adverse events during the study (ophthalmic examination, adverse events spontaneously reported)</description>
          <population>52 year old white male</population>
          <units>Incidences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Safety</title>
        <description>Incidence and severity of systemic adverse events during the study (clinical laboratory, adverse events spontaneously reported).</description>
        <time_frame>measured at day 1, and week 1, 4, 8, 12, 16, 24, 36, 52</time_frame>
        <population>52 year old white male</population>
        <group_list>
          <group group_id="O1">
            <title>Riboflavin Cross-linked Donor Cornea</title>
            <description>The donor cornea used as a carrier for the Boston Keratoprosthesis underwent crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
Riboflavin: Used to treat donor cornea before implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Safety</title>
          <description>Incidence and severity of systemic adverse events during the study (clinical laboratory, adverse events spontaneously reported).</description>
          <population>52 year old white male</population>
          <units>Incidences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This study enrolled one study subject. The study subject was followed for Adverse Events from the time of signing the study informed consent form 2/12/2013 to one year post surgery 3/13/2014</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Riboflavin Cross-linked Donor Cornea</title>
          <description>The donor cornea used as a carrier for the Boston Keratoprosthesis underwent crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
Riboflavin: Used to treat donor cornea before implantation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joseph Ciolino, MD</name_or_title>
      <organization>Massachusetts Eye and Ear Infirmary</organization>
      <phone>617-573-4437</phone>
      <email>joseph_ciolino@meei.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

